WHO’s classification of hepatitis D virus as carcinogenic raises urgent questions for vaccination, screening, and treatment strategies worldwide.

Recent advancements in cancer immunotherapy have highlighted glypican-3 (GPC3) as a prominent target for treating hepatocellular carcinoma (HCC). However, approximately 10% to 30% of HCC patients ...

What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and providers in The Beam, published monthly.

GLI’s #OctoberIs4Livers Campaign Calls for Collective Action on Early Detection and ScreeningWashington, D.C., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Today is the start of Global Liver Institute’s annual ...

A Memphis teen who has already endured unimaginable health challenges got to celebrate her quinceañera as planned this summer — and her Cinderella-like gown, ornate crown and shimmering jewelry helped ...

Preserved liver function and absence of metabolic dysfunction-associated steatotic liver disease or varices were associated with longer survival.

Discover a study on hepatocellular carcinoma showing how low-molecular-weight fucoidan enhances tumour control and preserves liver function with TACE.

Surrounded by loved ones in August, her quinceañera was more than a birthday celebration — it was a milestone of resilience, courage and determination When it came time for her quinceañera, a teen ...

Discover a study showing how HCV eradication with antivirals during immunotherapy improves survival, liver function, and treatment outcomes in advanced hepatocellular carcinoma.

A recent study published in Current Pharmaceutical Analysis explores the role of Salvia miltiorrhiza compounds in hepatocellular carcinoma (HCC). Researchers identified potential diagnostic biomarkers ...

One patient has glioblastoma multiforme (GBM), and the other patient has advanced hepatocellular carcinoma (HCC) treated in the second line. Neither patient has experienced PIC-related adverse events ...

Early on-treatment LSM accurately predicts liver-related events in chronic hepatitis B with significant fibrosis and cirrhosis. Liver-related event (LRE) risk is better predicted by liver stiffness ...